Liver disease driven by chronic alcohol use remains one of the most prevalent yet underdiscussed contributors to premature mortality in high-income countries — and a JAMA narrative review suggests the clinical gap between what we know and what gets implemented in practice remains stubbornly wide. For health-conscious adults, this matters not because moderate drinking headlines have shifted, but because the biological progression from early steatosis to cirrhosis and hepatocellular carcinoma is often clinically silent until irreversible damage has occurred.
The review synthesizes current understanding of alcohol-related liver disease (ALD) across its full spectrum: hepatic steatosis, alcoholic hepatitis, and cirrhosis. It examines epidemiological burden — ALD now accounts for nearly half of all liver-related deaths globally — and evaluates diagnostic approaches including non-invasive biomarker panels and imaging modalities increasingly displacing biopsy in clinical staging. On the treatment side, the review addresses corticosteroid efficacy in severe alcoholic hepatitis, the Lille score as a treatment-response predictor, and emerging evidence around early liver transplantation for select non-abstinent patients, a paradigm shift from historically absolute abstinence requirements.
For the broader research landscape, ALD sits at a complex intersection of hepatology, addiction medicine, and behavioral science — and this review's value lies in consolidating rapidly evolving evidence into a single clinical framework. Key limitations are inherent to the narrative format: the absence of a systematic search protocol introduces selection bias, and few of the treatments reviewed carry high-certainty evidence from large randomized trials. The corticosteroid debate, for instance, remains unresolved beyond short-term survival benefit. For longevity-focused readers, the most actionable signal here is mechanistic: hepatic inflammation and fibrosis pathways activated by alcohol overlap substantially with metabolic liver disease, making this a relevant framework well beyond the heaviest drinkers. An incremental but clinically useful synthesis.